• Welcome, introductions, goals (by M Pai) [Slides]
• The Big Picture: Global Value Chain for TB Diagnostics (by M Pai & A Suresh) [Slides]
• The Struggle to Get Diagnosed: Patient Perspectives on TB Diagnosis (by N Venkatesan & D Chavan) [Not available]
• Panel Discussion: Scale-up of WHO-endorsed diagnostics — Country Experiences & Challenges [Not available]
• TB Diagnostics Pipeline & Landscape (by C Denkinger) [Not available]
• Panel Discussion: Can Industry and Donors fill the gaps? [Not available]
• Introducing Accelerator for Impact (a4i) (by S Botwright) [Slides]
• To test or not to test? Ending the age-old debate for DR-TB (by J Furin) [Slides]
• Panel Discussion: Aligning the emerging TB drug and diagnostic pipelines [Not available]

Day 2 – 20 June 2017

• Next-generation TB tests: what do we need? (by S Schumacher) [Slides]
• Xpert MTB/RIF Ultra & GeneXpert OMNI: status update (by S Schumacher) [Slides]
• Chest radiology & CAD: state of the art (by F Khan) [Not available]
• Panel Discussion: Triage testing: options & prospects [Not available]
• Panel Discussion: Advances in pediatric TB diagnosis [Not available]
• QFT-Plus: what is the evidence? (by N Banaei) [Slides]
• Urine LAM detection: current status and future prospects (by P Drain) [Not available]
• TB Tech Pitch [Not available]

Day 3 – 21 June 2017

• Implementation Science – rationale and application to TB diagnostics research (by A Katamba) [Slides]
• IPAQT model for private sector access in India: lessons learnt (by M Sabharwal) [Slides]
• Qualitative research: how can it improve product design and implementation? (by N Engel) [Slides]
• Debate: Decentralized vs. Centralized TB testing (M Pai vs. M Salfinger) [Not available]
• Improving case notifications & quality in the Indian private sector (by I Farooq & N Jha & S Sarin) [Not available]
• Do we need a GAVI for diagnostics? (by P Drain) [Not available]
• Panel discussion: Real-time sequencing of MTB: are we there yet? [Not available]
• Panel discussion: Can we predict progression from latent to active TB? [Slides]

Day 4 – 22 June 2017

• Systematic reviews of diagnostic accuracy (by K Steingart) [Slides]
• SR: case study: Line probe assays (by R Nathavitharana) [Not available]
• SR: case study: Rapid CRP as a triage test (by C Yoon with recent updates from P Drain) [Slides]
• Guideline development in TB diagnostics (by K Steingart) [Slides]
• Panel discussion: How do countries make policies on new diagnostics? [Not available]
• Panel discussion: Universal DST: what does it mean for stakeholders? [Not available]
• Advocacy for improving TB diagnosis & care [Slides 1] [Slides 2] [Slides 3] [Slides 4]

Day 5 – 23 June 2017

• Modeling of TB diagnostics (by D Dowdy) [Not available]
• Challenges in modeling TB diagnostics (by D Dowdy) [Not available]
• Cost effectiveness analysis of TB diagnostics (by D Dowdy) [Not available]
• Case studies in modeling & cost-effectiveness (by D Dowdy) [Not available]
• Panel discussion: Linking models to decision-making in public health & policy [Not available]
• Modeling and cost effectiveness: a synthesis (by D Dowdy) [Not available]